A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)

  • By

  • September 15, 2026

  • 1 min

Share

Clinical Scorecard: A Trial of Intraperitoneal Paclitaxel Plus Chemotherapy Given Through a Vein in the Arm for Gastric Cancer (NCT07001748)

At a Glance

CategoryDetail
ConditionGastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis
Key MechanismsThe study asks whether paclitaxel administered directly into the abdominal cavity, in addition to chemotherapy given through a vein in the arm, can reduce the chance of gastric cancer growing or spreading and help patients live longer.
Target PopulationThe listed diseases are gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis; specific eligibility criteria are not provided.
Care SettingThe study compares paclitaxel administered directly into the abdominal cavity in addition to chemotherapy given through a vein in the arm with the usual approach for gastric cancer.

Key Highlights

  • The study asks whether adding paclitaxel administered directly into the abdominal cavity to chemotherapy given through a vein in the arm can reduce the chance of gastric cancer growing or spreading.
  • The study also asks whether this approach can help patients live longer.
  • The source does not report trial results.

Guideline-Based Recommendations

Diagnosis

    Management

    • The study evaluates intraperitoneal paclitaxel added to chemotherapy given intravenously; it does not provide a treatment recommendation.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        The listed diseases are gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis. Specific eligibility criteria are not provided.

        The study asks about adding paclitaxel administered into the abdominal cavity to chemotherapy given through a vein in the arm; the source describes the comparison as the usual approach for gastric cancer.

        Clinical Best Practices

        • For eligibility information, the source directs patients to contact the study team at 215-214-1515 or use the trial inquiry form.
        • The source directs readers to ClinicalTrials.gov for the full clinical trial description.

        Related Resources & Content

        Original Source(s)

        Related Content